UCHL1 and plasma cell myeloma: Compound 1 displayed growth inhibition against B cell and lung cancer cell lines (KMS11 and SW1271) possessing high endogenous UCHL1 expression and sensitivity towards UCHL1 knockdown, but also moderate efficacy against a myeloma cell line (KMS12), which has low UCHL1 expression and does not depend on UCHL1 for proliferation, confirming that this compound has important off-target effects.